NCT01098461View on ClinicalTrials.gov

Dose Ranging Study of Albiglutide in Japanese Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

215

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions
Diabetes Mellitus, Type 2
Interventions
BIOLOGICAL

albiglutide

subcutaneous injection of albiglutide

BIOLOGICAL

placebo

subcutaneous injection of placebo to match albiglutide

Trial Locations (30)

466-0815

GSK Investigational Site, Aichi

790-0067

GSK Investigational Site, Ehime

810-0001

GSK Investigational Site, Fukuoka

811-1346

GSK Investigational Site, Fukuoka

815-8555

GSK Investigational Site, Fukuoka

819-0168

GSK Investigational Site, Fukuoka

731-0103

GSK Investigational Site, Hiroshima

003-0023

GSK Investigational Site, Hokkaido

044-0053

GSK Investigational Site, Hokkaido

061-1395

GSK Investigational Site, Hokkaido

080-0010

GSK Investigational Site, Hokkaido

080-0016

GSK Investigational Site, Hokkaido

310-0826

GSK Investigational Site, Ibaraki

311-0113

GSK Investigational Site, Ibaraki

891-0401

GSK Investigational Site, Kagoshima

210-0852

GSK Investigational Site, Kanagawa

235-0045

GSK Investigational Site, Kanagawa

862-0976

GSK Investigational Site, Kumamoto

866-0862

GSK Investigational Site, Kumamoto

980-0021

GSK Investigational Site, Miyagi

985-0852

GSK Investigational Site, Miyagi

856-0831

GSK Investigational Site, Nagasaki

355-0321

GSK Investigational Site, Saitama

362-0021

GSK Investigational Site, Saitama

329-0101

GSK Investigational Site, Tochigi

329-0433

GSK Investigational Site, Tochigi

125-0054

GSK Investigational Site, Tokyo

154-0015

GSK Investigational Site, Tokyo

177-0041

GSK Investigational Site, Tokyo

990-0885

GSK Investigational Site, Yamagata

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY